Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 2002

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions
Prostate Cancer
Interventions
DRUG

MDX-010 / MDX-010 + Docetaxel

Trial Locations (11)

17033

Milton S. Hershey Medical Center, Hershey

29572

Grand Strand Urology, Myrtle Beach

70112

LSU Health Science Center/ Stanley S. Scott Cancer Center (uptown campus), New Orleans

76012

Urology Associates of North Texas, Arlington

84106

Utah Cancer Specialists, Salt Lake City

84124

Salt Lake Research, Salt Lake City

85712

Advanced Clinical Therapeutics, Tucson

90813

Pacific Shores Medical Group, Long Beach

92101

San Diego Uro-Research, San Diego

02906

University Urological Research Institute, Providence

98109-1023

Seattle Cancer Center Alliance, Seattle

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY